Institutions Own 33% of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Shares but Private Equity Firms Control 44% of the Company
Tenaya Therapeutics' Strategic Advantages in Cardiovascular Genetic Medicine Garner Buy Rating
Optimistic Buy Rating for Tenaya Therapeutics Based on Promising Gene Therapy Pipeline and Upcoming Clinical Milestones
20 Countries With the Highest Heart Disease Deaths Per Capita
Chardan Capital Reiterates Buy on Tenaya Therapeutics, Maintains $20 Price Target
Chardan Capital analyst Geulah Livshits reiterates Tenaya Therapeutics with a Buy and maintains $20 price target.
Analysts' Opinions Are Mixed on These Healthcare Stocks: Vera Therapeutics (VERA), Tyra Bioscience (TYRA) and Tenaya Therapeutics (TNYA)
Buy Rating Affirmed for Tenaya Therapeutics: A Combination of Solid Financials and Promising Clinical Pipeline
Analysts Are Bullish on Top Healthcare Stocks: Tenaya Therapeutics (TNYA), Sera Prognostics (SERA)
Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity
Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity
Canaccord Genuity Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $18
Canaccord Genuity analyst Whitney Ijem maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and lowers the price target from $19 to $18.
Tenaya Therapeutics Inc Reports Full Year and Q4 2023 Financial Results
HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $18 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $18 price target.
Tenaya Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/19/2024 273.44% HC Wainwright & Co. → $18 Reiterates Buy → Buy 11/30/2023 45.23% Leerink Partners → $7
Analysts' Top Healthcare Picks: Inventiva (IVA), Tenaya Therapeutics (TNYA)
Buy Rating Justified by Tenaya Therapeutics' Strong Financials and Promising Cardiovascular Pipeline Progress
TD Cowen Keeps Their Buy Rating on Tenaya Therapeutics (TNYA)
Tenaya Therapeutics Q4 EPS $(0.40) Beats $(0.44) Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.44) by 9.09 percent. This is a 34.43 percent increase over losses of $
Press Release: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Initial Data from Ongoing MyPeak(TM)-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expect
Tenaya Therapeutics 4Q Loss/Shr 40c >TNYA
Tenaya Therapeutics 4Q Loss/Shr 40c >TNYA
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) PKP2 Gene Replacement Therapy Normalized Heart Rhythms, Reversed
No Data